Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GTBP 
GT Biopharma Inc (GTBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GTBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.46% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.14M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 1.39 | 52 Weeks Range 1.72 - 4.10 | Updated Date 06/30/2025 |
52 Weeks Range 1.72 - 4.10 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.32% | Return on Equity (TTM) -538.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1367902 | Price to Sales(TTM) - |
Enterprise Value 1367902 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.09 | Shares Outstanding 3148000 | Shares Floating 1465866 |
Shares Outstanding 3148000 | Shares Floating 1465866 | ||
Percent Insiders 23.16 | Percent Institutions 18.98 |
Analyst Ratings
Rating 1 | Target Price 11 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GT Biopharma Inc
Company Overview
History and Background
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy products based on its TriKEu00ae and TetraKEu00ae platforms. Founded to address unmet needs in cancer treatment, the company leverages its platforms to target and kill cancer cells using the patient's own immune system. It was previously known as Oxis International, Inc., and changed its name to GT Biopharma, Inc. in March 2017.
Core Business Areas
- NK Cell Engager Immunotherapies: GT Biopharma is developing novel immunotherapies that harness the power of natural killer (NK) cells to fight cancer. Their TriKEu00ae and TetraKEu00ae platforms are designed to engage NK cells and direct them to kill cancer cells.
Leadership and Structure
The leadership team includes individuals with experience in biopharmaceutical development, clinical trials, and corporate management. The organizational structure comprises research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- GTB-3550 TriKE: GTB-3550 is a TriKEu00ae (Tri-specific Killer Engager) molecule targeting CD33+ cancers, primarily acute myeloid leukemia (AML). It's designed to redirect NK cells to kill AML cells. Clinical trials are ongoing. Competition exists from companies developing similar NK cell engager therapies and established AML treatments like chemotherapy and targeted therapies. Market share data is unavailable.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth, driven by advancements in immunotherapy and targeted therapies. There's significant interest in NK cell-based therapies as a promising approach to cancer treatment.
Positioning
GT Biopharma is positioned as an innovator in the NK cell engager immunotherapy space. Their TriKEu00ae and TetraKEu00ae platforms offer a unique approach to targeting and killing cancer cells. Competitive advantages include their proprietary platforms and clinical development programs.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated to be in the tens of billions of dollars. GT Biopharma is positioned to capture a portion of this market by developing effective NK cell-based therapies for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Proprietary TriKEu00ae and TetraKEu00ae platforms
- Focus on NK cell engager immunotherapies
- Clinical development programs for various cancer indications
- Experienced leadership team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Competition from larger, more established biopharmaceutical companies
- The company has a history of operating losses.
Opportunities
- Potential for breakthrough therapies in cancer treatment
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results leading to increased investor confidence
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy approaches
- Patent challenges
- Difficulties in raising capital.
Competitors and Market Share
Key Competitors
- NK
- SLDB
- AFFM
Competitive Landscape
GT Biopharma faces competition from other companies developing NK cell-based therapies and established cancer treatments. Their advantages lie in their proprietary platforms, while disadvantages include limited resources and reliance on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: GT Biopharma's historical growth has been characterized by research and development progress, clinical trial advancements, and fundraising activities. Revenue generation is still limited as they are in the clinical stage.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely due to the inherent risks in biopharmaceutical development.
Recent Initiatives: Recent initiatives include advancing clinical trials for GTB-3550 and exploring new applications for their TriKEu00ae and TetraKEu00ae platforms.
Summary
GT Biopharma is a clinical-stage company with promising technology in NK cell engager immunotherapy. Its TriKEu00ae and TetraKEu00ae platforms offer a unique approach to targeting cancer, but its future success depends heavily on clinical trial outcomes and securing additional funding. The company faces significant competition and regulatory hurdles but has the potential to deliver breakthrough cancer therapies. Its small market share relative to competitors illustrates its high risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment in GT Biopharma Inc. involves significant risks. Market share is estimated due to lack of available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GT Biopharma Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2017-09-22 | CEO & Executive Chairman Mr. Michael Martin Breen L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.gtbiopharma.com |
Full time employees 1 | Website https://www.gtbiopharma.com | ||
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.